CD56-enriched donor cell infusion after post-transplantation cyclophosphamide for haploidentical transplantation of advanced myeloid malignancies is associated with prompt reconstitution of mature natural killer cells and regulatory T cells with reduced incidence of acute graft versus host disease: A pilot study

Autor: Sarita Rani Jaiswal, Paul O'Donnell, Shamsur Zaman, Prakash Bhakuni, Murugaiyan Nedunchezhian, Aditi Chakrabarti, Kanika Sharma, Sheh Rawat, Margoob Ahmed, Suparno Chakrabarti
Rok vydání: 2017
Předmět:
Male
Cancer Research
Transplantation Conditioning
Myeloid
Graft vs Host Disease
Pilot Projects
Disease
T-Lymphocytes
Regulatory
0302 clinical medicine
Immunology and Allergy
Child
Genetics (clinical)
Histocompatibility Testing
Incidence
Incidence (epidemiology)
hemic and immune systems
Middle Aged
Phenotype
CD56 Antigen
Tissue Donors
Killer Cells
Natural
medicine.anatomical_structure
Oncology
Child
Preschool
Hematologic Neoplasms
030220 oncology & carcinogenesis
Disease Progression
Female
medicine.drug
Adult
Adolescent
Cyclophosphamide
Immunology
chemical and pharmacologic phenomena
CD16
Drug Administration Schedule
Donor lymphocyte infusion
Young Adult
03 medical and health sciences
Immune system
medicine
Humans
Transplantation
Homologous
Aged
Peripheral Blood Stem Cell Transplantation
Transplantation
business.industry
Cell Biology
Haplotypes
Feasibility Studies
business
030215 immunology
Zdroj: Cytotherapy. 19:531-542
ISSN: 1465-3249
Popis: We conducted a pilot study on the feasibility of CD56-enriched donor cell infusion after post-transplantation cyclophosphamide (PTCy) for 10 patients with advanced myeloid malignancies undergoing haploidentical peripheral blood stem cell transplantation with cyclosporine alone as graft-versus-host disease (GVHD) prophylaxis and compared the outcome and immune reconstitution with a control group of 20 patients undergoing the same without CD56-enriched donor cell infusion. An early and rapid surge of mature NK cells as well as CD4 + T cells and regulatory T cells (Tregs) was noted compared with the control group. KIR of donor phenotype reconstituted as early as day 30 with expression of CD56 dim CD16 + NKG2A − KIR + phenotype. None experienced viral or fungal infections, and non-relapse mortality was 10% only. The incidence of grade 2–4 acute GVHD was 50% in the control group with none in the CD56 group ( P = 0.01). Only two had de novo chronic GVHD in each group. Relapse occurred in five patients in CD56 group with a median follow-up of 12 months, similar to the control group. Our preliminary data show that CD56 + donor cell infusion after PTCy and short-course cyclosporine is feasible with prompt engraftment, rapid reconstitution of CD4 + T cells, Tregs and NK cells and reduced incidence of acute GVHD.
Databáze: OpenAIRE
Externí odkaz: